Sarcomatoid carcinoma of the prostate a clinicopathologic study of 12 patients

Shannon, Rhonda L.; Ro, Jae Y.; Grignon, David J.; Ordóñez, Nelson G.; Johnson, Douglas E.; Mackay, Bruce; Têtu, Bernard; Ayala, Alberto G.

doi:10.1002/1097-0142(19920601)69:11<2676::aid-cncr2820691109>3.0.co;2-p

Cited by 88 publications

(34 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[8][9][10] Tumors are most commonly composed of an admixture of both malignant glandular and spindle cell elements, in which cases with predominantly a sarcomatoid component may be mistaken for a sarcoma. In support of the term 'sarcomatoid carcinoma' it has been demonstrated that both the malignant epithelial and spindle cell components are clonally related.…”

Section: Sarcomatoid Carcinoma Of the Prostatementioning

confidence: 99%

Spindle cell lesions of the adult prostate

et al. 2007

View full text Add to dashboard Cite

Prostatic spindle cell lesions are diagnostically challenging and encompass a broad array of benign and malignant processes. A subset of these lesions arises only within the prostate and generally represents entities that originate from the prostate epithelium or stroma, such as sclerosing adenosis, sarcomatoid carcinoma, stromal tumors of uncertain malignant potential (STUMP), and stromal sarcoma. Another subset of spindle cell tumors that involve the prostate are also found at other sites and include solitary fibrous tumor, leiomyosarcoma, and neural lesions among others. Finally, tumors may secondarily involve the prostate yet present as primary prostatic processes, as is evident with several cases of gastrointestinal stromal tumors (GIST). The utility of ancillary studies, including immunohistochemistry, is often limited and the main criteria for diagnosis are the morphologic findings by routine H&E stain. This review addresses the various entities that may present as spindle cell tumors within the adult prostate and discusses the functional aspects of the differential diagnosis of these lesions.

show abstract

Section: Sarcomatoid Carcinoma Of the Prostatementioning

confidence: 99%

Spindle cell lesions of the adult prostate

et al. 2007

View full text Add to dashboard Cite

show abstract

“…15 These tumors are rare, but do occur in the prostate gland. [65][66][67][68][69][70][71][72] Clinically, these patients tend to be older and in roughly half of cases have a history of prostatic adenocarcinoma treated by radiation. 66,68 The tumors produce bladder outlet obstruction and often require repeated TURs to control local symptoms.…”

Section: Sarcomatoid Carcinomamentioning

confidence: 99%

“…66,68,73 In adults, these are almost always leiomyosarcoma and will stain appropriately. In recurrent tumors, the mesenchymal component usually overgrows the epithelial and so a pure sarcomatous pattern in the setting of pretreated adenocarcinoma should be assumed to represent sarcomatoid carcinoma.…”

Section: Sarcomatoid Carcinomamentioning

confidence: 99%

Unusual subtypes of prostate cancer

2004

View full text Add to dashboard Cite

The vast majority of prostatic tumors developing in adult males are adenocarcinomas. For the most part, variations in histology have not received specific designations and, from a practical approach, have had any specific prognostic implications handled through application of the Gleason grading system. Nonetheless, some of the adenocarcinoma variants have specific clinical features and differential diagnoses. Furthermore, there has been some controversy regarding the appropriate application of the Gleason grading scheme in these tumors. In addition, there are carcinomas that are in fact not adenocarcinomas and that should be kept as distinct entities. In this paper, the histologic variants of adenocarcinoma are reviewed with emphasis on clinicopathologic features and the clinical relevance of these subtypes. Other carcinomas that occur in the prostate gland are also discussed again with a focus on the clinicopathologic characteristics.

show abstract

“…PPC is defined as a poorly-differentiated NSCLC with ≥10% giant and/or spindle cell components, or as a carcinoma comprised completely of giant and spindle cells in the new WHO Classification of Lung Cancers (13). PPC is believed to be more aggressive and exhibit a poorer prognosis than ordinary lung carcinomas (1,3,14). There are few studies with regard to the chemotherapy of PPC, and its clinical and pathological characteristics therefore remain unclear.…”

Section: Discussionmentioning

confidence: 99%

Successful treatment of two consecutive cases of pulmonary pleomorphic carcinoma with platinum chemotherapy

et al. 2015

View full text Add to dashboard Cite

Abstract. Pulmonary pleomorphic carcinoma (PPC) is a rare pulmonary malignant tumor that has a more aggressive clinical course and a poorer prognosis compared with non-small cell lung cancer (NSCLC) due to its resistance to chemotherapy and radiotherapy. In patients with advanced or relapsed PPC, it has been reported that the response rate to chemotherapy regimens known to be effective in patients with NSCLC is only 0-17%. The present study reports the cases of two consecutive patients with advanced PPC who exhibited marked responses to chemotherapy with carboplatin plus paclitaxel chemotherapy and long-term survival without tumor progression. This suggests that carboplatin plus paclitaxel chemotherapy is a good option for the treatment of advanced PPC. IntroductionPulmonary pleomorphic carcinoma (PPC) is a rare primary malignant tumor in which carcinomatous and sarcomatous elements occur. The occurrence of the disease is extremely rare, accounting for only 0.1-0.4% of all reported malignant lung tumors (1-4). Patients with PPC are reported to be predominantly male smokers with a mean age of 66 years (5-8). PPC generally exhibits an aggressive clinical course, and has a tendency to grow rapidly and invade adjacent structures in the early stage. The recurrence after surgical treatment is common, and systemic metastases are frequently observed in patients with PPC (8). The prognosis of PPC is significantly worse than the majority of other subsets of non-small cell lung cancer (NSCLC) due to its poorer response to chemotherapy and radiotherapy. The response rate to chemotherapy regimens commonly used for NSCLC is in the range of 0-17% (2,9) and the median survival reported for patients with PPC was 5-10 months (1,2,9). The present study reports two cases of advanced PPC that were successfully treated with carboplatin plus paclitaxel chemotherapy and/or radiotherapy. Case reportCase 1. A 66-year-old male was admitted to the Otsu Red Cross Hospital (Otsu, Shiga, Japan) in May 2013, due to a persistent cough and dyspnea that had persisted for 10 days. The patient had previously undergone a surgical resection of the colon due to a gastrointestinal stromal tumor. The patient had also smoked two packs of cigarettes per day for 37 years. A performance status score of 1, according to the Eastern Cooperative Oncology Group (ECOG) scale (10), was recorded. Computed tomography (CT) of the chest showed a large tumor, measuring 100x80 mm, in the right lower lobe of the lung, with pleural effusion. An ultrasonography-guided percutaneous lung biopsy was performed, and the tumor specimen consisted of epithelioid and sarcomatous cells (Fig. 1A). On immunohistochemical staining, pankeratin was diffusely positive in the epithelioid and sarcomatous components (Fig. 1B). The patient was diagnosed with PPC based on the morphological findings of the tumor cells admixed with sarcomatoid and epithelioid cells. There was no evidence of metastasis to the other organs, corresponding to a diagnosis of clinical stage Ⅳ (cT4N0M1a) in the TNM cla...

show abstract

Sarcomatoid carcinoma of the prostate a clinicopathologic study of 12 patients

Cited by 88 publications

References 22 publications

Spindle cell lesions of the adult prostate

Spindle cell lesions of the adult prostate

Unusual subtypes of prostate cancer

Successful treatment of two consecutive cases of pulmonary pleomorphic carcinoma with platinum chemotherapy

Contact Info

Product

Resources

About